Development, validation, and implementation of an UHPLC-MS/MS method for the quantitation of furosemide in infant urine samples.
Development, validation, and implementation of an UHPLC-MS/MS method for the quantitation of furosemide in infant urine samples.
复制标题
DOI：
10.1002/bmc.5262
复制
发表时间：
2022-03
期刊：
影响因子：
--
通讯作者：
Moorthy GS
中科院分区：
文献类型：
--
作者：
Vedar C;Bamat NA;Zuppa AF;Reilly ME;Moorthy GS
速尿是一种利尿药，用于增加尿流量，以减少体内的盐和水的量。它通常用于治疗患有早产儿慢性肺病的早产儿。需要一种简单可靠的人尿中呋塞米的定量方法。我们开发并验证了一种用于人尿液中呋塞米定量的超高效液相色谱-串联质谱法，测定范围为0.100 - 50.0 μg/mL。样品制备包括用10 μL尿液进行固相萃取。质控样品的日内准确度和精密度范围分别为94.5 - 106%和1.86 - 10.2%，而日间准确度和精密度范围分别为99.2 - 102%和3.38 - 7.41%。呋塞米的平均回收率为23.8%，平均基质效应为101%。在测定条件下，呋塞米在人尿液中稳定。呋塞米在1周（室温、4 °C、−20 °C和−78 °C）、6个月（−78 °C）和3次冻融循环下显示稳定性。该耐用性测定证明了对少量（10 μL）人尿液中呋塞米的准确和精密定量。目前正在一项正在进行的儿科临床研究中实施。
Furosemide is a diuretic drug used to increase urine flow in order to reduce the amount of salt and water in the body. It is commonly utilized to treat preterm infants with chronic lung disease of prematurity. There is a need for a simple and reliable quantitation of furosemide in human urine. We have developed and validated an ultra-high performance liquid chromatographic-tandem mass spectrometry method for furosemide quantitation in human urine with an assay range of 0.100 – 50.0 μg/mL. Sample preparation involved solid-phase extraction with 10 μL of urine. Intra-day accuracies and precisions for the quality control samples ranged from 94.5 – 106% and 1.86 – 10.2%, respectively, while inter-day accuracies and precision ranged from 99.2 – 102% and 3.38 – 7.41%, respectively. Recovery for furosemide had an average of 23.8%, with an average matrix effect of 101%. Furosemide was stable in human urine under the assay conditions. Stability for furosemide was shown at 1 week (room temperature, 4 °C, −20 °C, and −78 °C), 6 months (−78 °C), and through three freeze-thaw cycles. This robust assay demonstrates accurate and precise quantitation of furosemide in a small volume (10 μL) of human urine. It is currently implemented in an ongoing pediatric clinical study.
登录
查看更多内容
影响因子：
5.4
作者：
Schmieder RE;Ott C;Schmid A;Friedrich S;Kistner I;Ditting T;Veelken R;Uder M;Toennes SW
通讯作者：
Toennes SW
DOI：
10.1001/archpediatrics.2011.161
发表时间：
2012-01-01
影响因子：
--
作者：
Feudtner, Chris;Dai, Dingwei;Metjian, Talene A.
通讯作者：
Metjian, Talene A.
影响因子：
3.4
作者：
Ayalasomayajula, Surya;Schuehly, Uwe;Langenickel, Thomas H.
通讯作者：
Langenickel, Thomas H.
影响因子：
2.5
作者：
Segar, JL;Chemtob, S;Bell, EF
通讯作者：
Bell, EF
影响因子：
5.1
作者：
MIROCHNICK, MH;MICELI, JJ;RAYE, JR
通讯作者：
RAYE, JR